What makes LNK01006 a potentially best-in-class TYK2 inhibitor with central immune impact?

By on    Pharma & Biotech  

What makes LNK01006 a potentially best-in-class TYK2 inhibitor with central immune impact?

Lynk Pharmaceuticals and Formation Bio have entered an exclusive licensing and development agreement for LNK01006, a next-generation, central nervous system (CNS)-penetrant TYK2 inhibitor. The deal gives Formation Bio global rights to the asset outside Greater China, with plans to initiate a Phase 1 clinical trial in the United States during the first half of 2026. […]

Can Gotenfia finally unlock biosimilar competition for Simponi in Europe?

By on    Pharma & Biotech  

Can Gotenfia finally unlock biosimilar competition for Simponi in Europe?

STADA Arzneimittel AG and Bio-Thera Solutions have secured a positive opinion from the European Medicines Agency’s Committee for Medicinal Products for Human Use for Gotenfia, a proposed biosimilar to the tumor necrosis factor alpha inhibitor golimumab. The product references Simponi, an originator drug widely prescribed for multiple autoimmune conditions. If approved, Gotenfia would be marketed […]

1 2